Allscripts Healthcare Solutions (NASDAQ:MDRX) updated its FY 2019 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $0.65-0.70 for the period, compared to the Thomson Reuters consensus estimate of $0.81. Allscripts Healthcare Solutions also updated its Q1 2019 guidance to EPS.
Shares of NASDAQ:MDRX traded down $0.22 during trading on Thursday, reaching $11.94. The company had a trading volume of 3,539,398 shares, compared to its average volume of 2,542,948. The firm has a market cap of $2.12 billion, a P/E ratio of 25.40, a P/E/G ratio of 1.79 and a beta of 1.40. Allscripts Healthcare Solutions has a twelve month low of $8.54 and a twelve month high of $14.97. The company has a current ratio of 0.94, a quick ratio of 0.94 and a debt-to-equity ratio of 1.61.
A number of analysts have recently weighed in on MDRX shares. Citigroup reduced their price target on shares of Allscripts Healthcare Solutions from $19.00 to $17.00 and set a buy rating for the company in a research note on Friday, November 2nd. Bank of America reduced their price target on shares of Allscripts Healthcare Solutions from $16.50 to $15.00 and set a buy rating for the company in a research note on Friday, November 2nd. BidaskClub raised shares of Allscripts Healthcare Solutions from a hold rating to a buy rating in a research note on Wednesday, January 9th. Zacks Investment Research raised shares of Allscripts Healthcare Solutions from a sell rating to a hold rating in a research note on Friday, November 30th. Finally, Argus lowered shares of Allscripts Healthcare Solutions from a buy rating to a hold rating in a research note on Wednesday, November 14th. Six equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $14.90.
In other news, insider Brian Farley sold 6,000 shares of the business’s stock in a transaction that occurred on Friday, January 18th. The shares were sold at an average price of $12.00, for a total transaction of $72,000.00. Following the sale, the insider now owns 235,673 shares in the company, valued at $2,828,076. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Richard J. Poulton sold 60,000 shares of the business’s stock in a transaction that occurred on Thursday, December 13th. The shares were sold at an average price of $9.82, for a total transaction of $589,200.00. Following the sale, the president now owns 479,520 shares in the company, valued at approximately $4,708,886.40. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 37,728 shares of company stock valued at $380,972. Company insiders own 1.10% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Allscripts Healthcare Solutions (MDRX) Releases FY 2019 Earnings Guidance” was originally posted by Zolmax and is owned by of Zolmax. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://zolmax.com/investing/allscripts-healthcare-solutions-mdrx-releases-fy-2019-earnings-guidance/2917668.html.
About Allscripts Healthcare Solutions
Allscripts Healthcare Solutions, Inc provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records, connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions.
Further Reading: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Allscripts Healthcare Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions and related companies with MarketBeat.com's FREE daily email newsletter.